High‐dose vs low‐dose colchicine
Total adverse events · acute gout
High‐dose may leads to higher total adverse events compared with low‐dose colchicine (low certainty).
1 finding from 1 review
- RR 2.11 [1.51, 2.95]1 study · 126 participantsLow
Findings
What do systematic reviews say?
8 questions · 8 findings · 5 reviews
No studies found 1 · 12.5%GRADE not reported 3 · 37.5%Very low 2 · 25%Low 2 · 25%Moderate 0 · 0%High 0 · 0%
High‐dose vs low‐dose colchicine
Serious adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 126 participantsGRADE not reported
High‐dose vs low‐dose colchicine
Withdrawals due to adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 126 participantsGRADE not reported
Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin
Adverse events · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
- Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
ASA + high‐dose LMWH vs ASA + low‐dose LMWH or UFH
Adverse events other than bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
- Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes onlyno estimate extracted1 participantsGRADE not reported
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)
Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
- Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 1080 participantsVery low
Summary of findings: high‐dose urate oxidase vs low‐dose urate oxidase
Frequency of adverse events ( · children with haematological malignancy at risk of tumour lysis syndrome
Summary of findings: high‐dose urate oxidase showed no clear difference in frequency of adverse events ( compared with low‐dose urate oxidase (low certainty).
1 finding from 1 review
- Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer 2017 · Cochrane Headline outcomes onlyRR 0.54 [0.12, 2.48]1 study · 29 participantsLow
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) vs low‐dose dexamethasone (6 mg to 8 mg)
Adverse events: all grades · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
- Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 98 participantsVery low